Welcome to our dedicated page for Immunocore Holdings news (Ticker: IMCR), a resource for investors and traders seeking the latest updates and insights on Immunocore Holdings stock.
Immunocore Holdings plc reports commercial and clinical developments for a biotechnology issuer whose Nasdaq-listed ADSs represent ordinary shares. The company uses its ImmTAX TCR bispecific immunotherapy platform across oncology, infectious disease and autoimmune programs, with KIMMTRAK (tebentafusp-tebn) approved for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia and the United Kingdom.
Recurring updates cover KIMMTRAK sales and long-term survival data, lifecycle-management studies in uveal and cutaneous melanoma, the PRAME-A02 candidate brenetafusp, earlier ImmTAX candidates, HIV functional-cure research, autoimmune disease pipeline activity, financial results, investor presentations and R&D governance changes.
The global cancer immunotherapy market is projected to reach USD 196.45 billion by 2030, growing at a CAGR of 7.2%, according to a report by Grand View Research. The increasing use of immunotherapy due to its targeted approach and heightened regulatory approvals for novel treatments are key growth factors. Monoclonal antibodies lead market share, while oncolytic viral therapies and vaccines are expected to grow rapidly. Lung cancer treatment is currently dominant, with a growing focus on prostate cancer. Notably, the Asia Pacific region is forecasted to experience the fastest growth driven by healthcare advancements and unmet medical needs.
Immunocore Holdings plc announced strategic priorities for 2023-2024, emphasizing pipeline expansion and the continued global rollout of KIMMTRAK (tebentafusp-tebn). The drug has been approved in over 30 countries with preliminary unaudited net sales of approximately $50 million for Q4 2022 and $140 million for the full year. Key priorities include the enrollment in IMC-F106C trials and the introduction of new ImmTAC candidates targeting PRAME and PIWIL1. The company aims to solidify KIMMTRAK as the first-line treatment for metastatic uveal melanoma.
Immunocore Holdings (Nasdaq: IMCR) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 9:00 a.m. PST. The company's management will engage in a fireside chat, which will be webcast live, and available on Immunocore's website. Immunocore specializes in pioneering T cell receptor bispecific immunotherapies, notably its approved oncology therapeutic, KIMMTRAK, intended for treating unresectable or metastatic uveal melanoma. The company is progressing on multiple clinical and pre-clinical programs across various disease areas.
Immunocore has won the Prix Galien France 2022 award in the ‘Medicine in Innovative Therapeutics’ category for its treatment KIMMTRAK (tebentafusp), the world’s first T cell receptor therapy for unresectable or metastatic uveal melanoma. Approved by the FDA and several health authorities in 2022, KIMMTRAK targets a rare and aggressive eye cancer that previously lacked specific treatments. This honor reflects both the therapy's impact on patients and the innovative technology developed by Immunocore, marking a successful year for the company.
Immunocore presented data for its bispecific T cell engager IMC-C103C targeting MAGE-A4 in ovarian cancer. The Phase 1 trial involved 33 heavily pre-treated patients. Results showed a manageable safety profile and some clinical activity, although the RECIST response rate was low among patients with low MAGE-A4 expression. Notably, reductions in ctDNA were observed even in patients with minimal MAGE-A4 expression. IMC-C103C is being co-developed with Genentech.
Immunocore Holdings plc (Nasdaq: IMCR) and Gadeta B.V. have entered a collaboration to develop the first gamma delta TCR ImmTAC® for treating solid tumors, including colorectal cancer. This partnership marries Gadeta's expertise in gamma delta TCRs with Immunocore's TCR bispecific engineering. Immunocore has an option for exclusive licensing of ImmTAC candidates resulting from this collaboration, and Gadeta is set to receive upfront fees and milestone payments. The new gamma delta TCRs exemplify a promising solution for patients without HLA restrictions.
Immunocore Holdings Plc (Nasdaq: IMCR) announced its participation in the 5th Annual Evercore ISI HealthCONx Conference scheduled for November 30, 2022, at 8:25 a.m. ET. The management will engage in a fireside chat, which will be available for live streaming and later as a replay on Immunocore's website.
Immunocore specializes in T cell receptor bispecific immunotherapies aimed at treating various diseases, including cancer and autoimmune disorders. Their lead product, KIMMTRAK, is approved for patients with metastatic uveal melanoma.
Immunocore has presented new data on KIMMTRAK (tebentafusp-tebn) for metastatic uveal melanoma at the SITC 2022 Annual Meeting. The analysis shows that gp100 protein expression remains unchanged relative to baseline during tumor progression. Notably, patients with progressive disease who maintain antigen processing machinery show longer overall survival. The study involved biopsies from 18 patients, highlighting a correlation between higher expression of antigen processing machinery components and better survival outcomes despite disease progression. KIMMTRAK aims to treat advanced melanoma effectively.
Immunocore Holdings Plc (Nasdaq: IMCR) will present at the Jefferies London Healthcare Conference on November 17, 2022, at 9:45 a.m. GMT. The presentation will be available via live webcast on Immunocore's website and a replay will follow temporarily. As a pioneering biotechnology company, Immunocore develops T cell receptor (TCR) bispecific immunotherapies targeting various diseases, including cancer. Their advanced treatment, KIMMTRAK, is approved for metastatic uveal melanoma in several key markets.
Immunocore reported Q3 2022 revenues of £36.3 million ($40.4 million) for KIMMTRAK, marking a 20% increase from Q2. The company's cash reserves stand at £347 million ($387 million). Clinical updates emphasize promising data from IMC-F106C targeting PRAME, highlighting its potential across tumor types. The company has expanded its prescribing accounts to 180 in the U.S. and received significant added benefit ratings in Germany. Additionally, Immunocore plans trials for tebentafusp in melanoma and other cancers, setting a positive outlook for continued growth.